In recent trading session, Agile Therapeutics, Inc. (NASDAQ:AGRX) saw 1,367,877 shares changing hands with its beta currently measuring 1.4. Company’s recent per share price level of $2.71 trading at $0.26 or 10.5% at recent trade assigns it a market valuation of $238.76 Million. That current trading price of AGRX’s stock is at a discount of -75.83% from its 52-week high price of $4.765 and is indicating a premium of 87.08% from its 52-week low price of $0.35. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 1.14 Million shares which gives us an average trading volume of 1.68 Million if we extend that period to 3-months.
For Agile Therapeutics, Inc. (AGRX), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.6. Splitting up the data highlights that, out of 4 analysts covering the stock, none rated the stock as a Sell while none recommended an Overweight rating for the stock. None suggested the stock as a Hold whereas 4 see the stock as a Buy. None analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -$0.18 in the current quarter.
Agile Therapeutics, Inc. (NASDAQ:AGRX) trade information
Upright in the green today for gaining 10.5%, in the last five days AGRX remained trading in the green while hitting it’s week-highest on Tuesday, Aug 11 when the stock touched $2.75-3 price level, adding 3.27% to its value on the day. Agile Therapeutics, Inc.’s shares saw a change of 6.4% in year-to-date performance and have moved 0.38% in past 5-day. Agile Therapeutics, Inc. (NASDAQ:AGRX) showed a performance of 9.02% in past 30-days. Number of shares sold short was 4.37 Million shares which calculate 2.6 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of $8.67 to the stock, which implies a rise of 219.93% to its current value. Analysts have been projecting $6 as a low price target for the stock while placing it at a high target of $12. It follows that stock’s current price would jump +342.8% in reaching the projected high whereas dropping to the targeted low would mean a loss of 121.4% for stock’s current value.
Agile Therapeutics, Inc. (AGRX) estimates and forecasts
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 23.2% during past 5 years. In 2020, company’s earnings growth rate is likely to be around 34.7% while estimates for its earnings growth in next 5 years are of 0%
Agile Therapeutics, Inc. (NASDAQ:AGRX)’s Major holders
Insiders are in possession of 0.69% of company’s total shares while institution are holding 38.86% percent of that, with stock having share float percentage of 39.13%. Investors also watch the number of corporate investors in a company very closely, which is 72 institutions for Agile Therapeutics, Inc. that are currently holding shares of the company. Perceptive Advisors Llc is the top institutional holder at AGRX for having 15.92 Million shares of worth $29.61 Million. And as of March 30, 2020, it was holding 18.24% of the company’s outstanding shares.
The second largest institutional holder is Investor AB, which was holding about 3.51 Million shares on March 30, 2020. The number of shares represents firm’s hold over 4.02% of outstanding shares, having a total worth of $6.53 Million.
On the other hand, Vanguard Total Stock Market Index Fund and Vanguard Extended Market Index Fund are the top two Mutual Funds which own company’s shares. As of March 30, 2020, the former fund manager was holding 2141840 shares of worth $3.98 Million or 2.45% of the total outstanding shares. The later fund manager was in possession of 1.06 Million shares on March 30, 2020, making its stake of worth around $1.97 Million in the company or a holder of 1.21% of company’s stock.